Stephenson Megan L, Hawkins J Seth, Powers Barbara L, Wing Deborah A
Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, University of California Irvine Medical Center, 101 The City Drive South, Building 56, Suite 800, Orange, CA 92868, USA.
Womens Health (Lond). 2014 Jan;10(1):29-36. doi: 10.2217/whe.13.49.
Labor induction and cervical ripening are widely utilized and new methods are constantly being investigated. Prostaglandins have been shown to be effective labor induction agents and, in particular, were compared with other prostaglandin preparations; vaginal misoprostol used off-label was associated with reduced failure to achieve vaginal delivery. The challenge is to provide this medication with the correct dosing for this indication and with the ability to discontinue the medication if needed, all while ensuring essential maternal and neonatal safety. The misoprostol vaginal insert initiates cervical ripening using a delivery system that controls misoprostol release and can be rapidly removed. This article reviews the development, safety and efficacy of the misoprostol vaginal insert for induction of labor and cervical ripening, and will focus on vaginally administered prostaglandins.
引产和促宫颈成熟被广泛应用,新方法也在不断研究中。前列腺素已被证明是有效的引产药物,特别是与其他前列腺素制剂进行了比较;非标签使用的阴道米索前列醇与降低阴道分娩失败率有关。挑战在于为该适应症提供正确剂量的药物,并在需要时能够停药,同时确保母婴基本安全。米索前列醇阴道栓剂使用一种控制米索前列醇释放且可快速取出的给药系统来启动宫颈成熟。本文综述了米索前列醇阴道栓剂用于引产和促宫颈成熟的研发、安全性和有效性,并将重点关注经阴道给药的前列腺素。